Lisa Haut
Family · Torrington, CTNPI 1962400150
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 692 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 26.6% of the total. 2025 is the largest year on record at $3,904, 2.1 times the $1,881 reported in 2021. Among family clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 692 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Johnson & Johnson$1K
- Corium, LLC$1K
- Neurocrine Biosciences, Inc.$737
- Teva Pharmaceuticals USA, Inc.$732
- plus $3K from 21 others
What the payments were for
- Food & beverage$12,93899%
- Education$1501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 206 | $3,486 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 137 | $2,327 |
| Johnson & Johnson | 62 | $1,325 |
| Corium, LLC | 67 | $1,144 |
| Neurocrine Biosciences, Inc. | 30 | $737 |
| Teva Pharmaceuticals USA, Inc. | 40 | $732 |
| Alkermes, Inc. | 18 | $558 |
| Otsuka America Pharmaceutical, Inc. | 20 | $374 |
| Lundbeck LLC | 19 | $342 |
| Gilead | 11 | $326 |
| Indivior Inc. | 12 | $308 |
| Novo Nordisk | 13 | $262 |
| Axsome Therapeutics, Inc. | 10 | $232 |
| USWM, LLC | 13 | $228 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $210 |
| Supernus Pharmaceuticals, Inc. | 4 | $86 |
| Braeburn Inc. | 4 | $82 |
| AstraZeneca | 3 | $68 |
| Sunovion Pharmaceuticals Inc. | 3 | $67 |
| Lilly USA, LLC | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| Almatica Pharma LLC | 1 | $25 |
| Ardelyx, Inc. | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Insulet Corporation | 1 | $15 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,088 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 117 | $162,973 |
| SpravatoEsketamine Hcl | 81 | $87,765 |
| RexultiBrexpiprazole | 40 | $62,519 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 194 | $34,626 |
| OzempicSemaglutide | 30 | $31,968 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 85 | $26,321 |
| Nurtec OdtRimegepant Sulfate | 19 | $24,162 |
| AuvelityDextromethorphan Hbr/Bupropion | 25 | $21,845 |
| VivitrolNaltrexone Microspheres | 12 | $21,599 |
| LinzessLinaclotide | 38 | $21,112 |
| VyvanseLisdexamfetamine Dimesylate | 37 | $14,509 |
| BelbucaBuprenorphine Hcl | 11 | $11,419 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,245 |
| EntrestoSacubitril/Valsartan | 12 | $7,360 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 100 | $6,334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Linzess | $3,486 | $184,085155 claims |
| Johnson & JohnsonSpravato | $1,325 | $87,76581 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $374 | $62,51940 claims |
| Novo NordiskOzempic | $262 | $31,96830 claims |
| Indivior Inc.Suboxone | $308 | $26,32185 claims |
| PfizerNurtec Odt | $14 | $24,16219 claims |
| Axsome Therapeutics, Inc.Auvelity | $232 | $21,84525 claims |
| Alkermes, Inc.Vivitrol | $558 | $21,59912 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $210 | $14,50937 claims |
| AstraZenecaBreztri Aerosphere | $68 | $8,24513 claims |
| Lilly USA, LLCOlanzapine | $55 | $75855 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.
Other family in Torrington
- David OhotnickyTorrington$24K
- Brandy StepneyTorrington$10K
- Elisha ChristiansonWaterbury$371K
- Kathryn TierneyNew Britain$140K
- Jennifer SilvaSouth Windsor$91K
- Carli WillardEnfield$74K
- Erin MartinMilford$70K
- Dayna GiordanoNew Haven$65K
- Diana BytyqiDerby$53K
- Farhiya AbdiSouth Windsor$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.